Tenax Therapeutics, Inc. (TENX) Institutional Ownership

Ownership Summary

Tenax Therapeutics, Inc. (NASDAQ:TENX) appears in 46 institutional 13F filings for the quarter ending December 2025.

• Their combined ownership stood at 17.7% of outstanding shares in December 2025, up from 11.9% in September 2025.
• They increased total shares held in Tenax Therapeutics by 64.88% from the prior quarter, while the number of investors in TENX increased 109.09% year over year.
• Of these 46 funds, 30 grew their exposure to Tenax Therapeutics, 3 cut back, and 13 maintained positions.
• Combined, these investors held 7.03Mn shares in TENX for December 2025, up by 2.76Mn shares quarter on quarter, and up 5.59Mn shares year over year.
• Janus Henderson Group Plc leads ownership in TENX with 3.63Mn shares as of December 31, 2025, equal to 9.14% of outstanding shares.
• Leading buyers of Tenax Therapeutics shares for the quarter ending December 2025 were Janus Henderson Group Plc (3.46Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.95Mn), Venrock Adviser, LLC (1.68Mn), PERCEPTIVE ADVISORS LLC (1.01Mn), Stonepine Capital Management, LLC (963.32K).
• Top sellers of TENX stock for the quarter ending December 2025 included DIADEMA PARTNERS LP (63.43K), SPHERA FUNDS MANAGEMENT LTD. (54.1K), Goldman Sachs Group Inc (12.96K), Corient Private Wealth LLC (12.39K), RTW INVESTMENTS, LP (8.1K).
• Per Business Quant data, the top 10 holders of Tenax Therapeutics for the quarter ending December 2025 are Janus Henderson Group Plc (3.63Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.95Mn), Venrock Adviser, LLC (1.68Mn), PERCEPTIVE ADVISORS LLC (1.45Mn), Ikarian Capital, LLC (1.02Mn), Stonepine Capital Management, LLC (975.2K), Logos Global Management LP (625.0K), Morgan Stanley (596.56K), Velan Capital Investment Management LP (583.33K), ADAGE CAPITAL PARTNERS GP, L.L.C. (540.13K).